9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends NMTR vs. OGEN, CELZ, APM, SNPX, INM, PTIX, HEPA, SNOA, ATXI, and CHROShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Oragenics (OGEN), Creative Medical Technology (CELZ), Aptorum Group (APM), Synaptogenix (SNPX), InMed Pharmaceuticals (INM), Protagenic Therapeutics (PTIX), Hepion Pharmaceuticals (HEPA), Sonoma Pharmaceuticals (SNOA), Avenue Therapeutics (ATXI), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Oragenics Creative Medical Technology Aptorum Group Synaptogenix InMed Pharmaceuticals Protagenic Therapeutics Hepion Pharmaceuticals Sonoma Pharmaceuticals Avenue Therapeutics Chromocell Therapeutics Oragenics (NYSE:OGEN) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment. Does the MarketBeat Community prefer OGEN or NMTR? 9 Meters Biopharma received 37 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformOragenicsOutperform VotesNo VotesUnderperform Votes37100.00% 9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Which has stronger valuation and earnings, OGEN or NMTR? Oragenics has higher revenue and earnings than 9 Meters Biopharma. Oragenics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenics$40K108.45-$20.66M-$7.07-0.059 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Is OGEN or NMTR more profitable? 9 Meters Biopharma's return on equity of -584.97% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% 9 Meters Biopharma N/A -584.97%-159.45% Does the media prefer OGEN or NMTR? In the previous week, Oragenics had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for Oragenics and 0 mentions for 9 Meters Biopharma. Oragenics' average media sentiment score of 0.25 beat 9 Meters Biopharma's score of 0.00 indicating that Oragenics is being referred to more favorably in the media. Company Overall Sentiment Oragenics Neutral 9 Meters Biopharma Neutral Which has more volatility and risk, OGEN or NMTR? Oragenics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Do institutionals and insiders believe in OGEN or NMTR? 18.7% of Oragenics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 10.1% of Oragenics shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Summary9 Meters Biopharma beats Oragenics on 8 of the 13 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$165.68M$5.14B$9.08BDividend YieldN/A3.64%5.09%4.23%P/E Ratio-0.02115.5190.1317.20Price / SalesN/A18,531.021,117.09117.04Price / CashN/A12.8743.1037.85Price / BookN/A8.594.784.78Net Income-$43.77M-$20.67M$120.31M$225.60M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220OGENOragenicsN/A$0.34+2.7%N/AN/A$4.14M$40,000.000.005Analyst ForecastNews CoverageGap UpCELZCreative Medical Technology0.5925 of 5 stars$2.31+5.5%N/A-55.2%$4.04M$10,000.00-0.615Positive NewsAPMAptorum Group0.3987 of 5 stars$0.76-1.2%N/A-66.2%$3.93M$431,378.000.0030News CoverageGap DownSNPXSynaptogenix1.3915 of 5 stars$2.80+4.1%$14.00+400.0%-54.5%$3.81MN/A0.004News CoverageINMInMed Pharmaceuticals0.4358 of 5 stars$5.20-1.1%N/A-36.5%$3.73M$4.96M-0.3813News CoveragePositive NewsGap DownPTIXProtagenic Therapeutics0.8347 of 5 stars$0.54+8.6%N/A-27.7%$3.65MN/A-0.391Positive NewsGap UpHEPAHepion PharmaceuticalsN/A$0.53-11.0%N/A-84.4%$3.65MN/A-0.1320SNOASonoma Pharmaceuticals0.5911 of 5 stars$2.71+1.5%N/A+1,608.9%$3.63M$12.73M0.00180ATXIAvenue Therapeutics2.1972 of 5 stars$1.75-2.8%N/A-83.3%$3.59MN/A0.104CHROChromocell TherapeuticsN/A$0.59+1.2%N/AN/A$3.57MN/A0.004 Related Companies and Tools Related Companies OGEN Alternatives CELZ Alternatives APM Alternatives SNPX Alternatives INM Alternatives PTIX Alternatives HEPA Alternatives SNOA Alternatives ATXI Alternatives CHRO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NMTR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
